Forte Biosciences (FBRX) Consolidated Net Income (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Consolidated Net Income data on file, last reported at -$22.1 million in Q1 2026.

• On a quarterly basis, Consolidated Net Income fell 41.39% year-over-year to -$22.1 million in Q1 2026; TTM through Mar 2026 was -$107.2 million, a 140.3% decrease from a year earlier, with the FY2025 full-year figure at -$73.5 million, down 2655.51% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$22.1 million, up from -$24.6 million in the prior quarter.
• Over the last five years, Consolidated Net Income for FBRX reached as high as -$2.8 million in Q1 2022 and fell as low as -$35.8 million in Q3 2025.
• Historically, Consolidated Net Income has averaged -$12.2 million across 5 years, with a median of -$8.7 million in 2024.
• Across the five-year window, Consolidated Net Income jumped 90.32% in 2022 and slumped 313.47% in 2025, its largest moves.
• Year by year, Consolidated Net Income stood at -$5.0 million in 2022, then dropped by 28.12% to -$6.4 million in 2023, then declined by 15.93% to -$7.4 million in 2024, then slumped by 231.19% to -$24.6 million in 2025, then increased by 10.07% to -$22.1 million in 2026.
• Per Business Quant data, the three most recent Consolidated Net Income figures were -$22.1 million in Q1 2026, -$24.6 million in Q4 2025, and -$35.8 million in Q3 2025.